UNSPSC 51381506: Morniflumate

This classification denotes an anti-infective agent with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R133MWH7X1, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 2-(4-morpholinylethyl) ester but generally known as morniflumate, which bears US NIH Compound Identifier 72106. European Medicines Agency schedules Morniflumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09068MIG.

UNSPSC 51381506 Morniflumate (Commodity) does not align with the recent state and local solicitation activity tagged to this code. The single recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the pharmaceutical scope of Morniflumate, a nonsteroidal anti-inflammatory drug. The source shows no recent state and local procurement activity for Morniflumate itself, indicating either sparse demand or a coding mismatch in the procurement systems capturing this category.

Seminole County's Naloxone procurement (IFB released July 10, 2023, response deadline July 26, 2023) seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually on a two-year term with a one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB requires electronic bid submission, E-Verify compliance, standard insurance coverage, and cost breakdowns by line item. Without additional recent opportunities specifically for Morniflumate or other products under this Commodity code, the business development signal is weak—either this code sees minimal state and local procurement activity, or issuing bodies are classifying similar drug purchases under different UNSPSC categories.